To evaluate associations between highdensity lipoprotein cholesterol (HDL) and non-HDL-C levels at specific ages and subsequent Alzheimer's disease (AD) risk. DESIGN: Prospective population-based cohort study. SETTING: Adult Changes in Thought (ACT) Study. PARTICIPANTS: Individuals aged 65 and older with no dementia at ACT Study entry. We identified separate, partially overlapping subcohorts of ACT participants who were eligible for each age band-specific analysis (50-59, n = 1,088; 60-69, n = 2,852; 70-79, n = 2,344; 80-89, n = 537). MEASUREMENTS: Exposure consisted of clinical measures of total cholesterol (TC) and HDL-C from laboratory data during a given age band. Outcomes of incident AD were assessed post-age band using standard research diagnostic criteria. Statistical analyses used adjusted Cox proportional hazards regression models for each exposure and outcome pair within an age band. Cholesterol exposures were modeled using cubic splines. RESULTS: For non-HDL-C, we found a statistically significant association with AD risk in the 60 to 69 (omnibus p = .005) and 70 to 79 (omnibus p = .04) age bands, suggesting a potential U-shaped relationship (greater risk at low and high levels). For example, in people aged 60 to 69, those with an average non-HDL-C level of 120 mg/DL had a 29% greater AD hazard (hazard ratio (HR)=1.29, 95% confidence interval (CI)=1.04-1.61) than those with an average non-HDL-C level of 160 mg/dL, whereas those with an average non-HDL-C level of 210 mg/dL had a 16% greater hazard (HR=1.16, 95% CI=1.01-1.33). We did not find a statistically significant association between HDL-C and AD risk. CONCLUSION: People with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60s and 70s had modestly higher risk of AD than those with intermediate (160 mg/dL) levels. The extreme age bands (50s and 80s) had small sample sizes.
† ¶ ¶ OBJECTIVES: To evaluate associations between highdensity lipoprotein cholesterol (HDL) and non-HDL-C levels at specific ages and subsequent Alzheimer's disease (AD) risk. DESIGN: Prospective population-based cohort study. SETTING: Adult Changes in Thought (ACT) Study. PARTICIPANTS: Individuals aged 65 and older with no dementia at ACT Study entry. We identified separate, partially overlapping subcohorts of ACT participants who were eligible for each age band-specific analysis (50-59, n = 1,088; 60-69, n = 2,852; 70-79, n = 2,344; 80-89, n = 537). MEASUREMENTS: Exposure consisted of clinical measures of total cholesterol (TC) and HDL-C from laboratory data during a given age band. Outcomes of incident AD were assessed post-age band using standard research diagnostic criteria. Statistical analyses used adjusted Cox proportional hazards regression models for each exposure and outcome pair within an age band. Cholesterol exposures were modeled using cubic splines. RESULTS: For non-HDL-C, we found a statistically significant association with AD risk in the 60 to 69 (omnibus p = .005) and 70 to 79 (omnibus p = .04) age bands, suggesting a potential U-shaped relationship (greater risk at low and high levels). For example, in people aged 60 to 69, those with an average non-HDL-C level of 120 mg/DL had a 29% greater AD hazard (hazard ratio (HR)=1.29, 95% confidence interval (CI)=1.04-1.61) than those with an average non-HDL-C level of 160 mg/dL, whereas those with an average non-HDL-C level of 210 mg/dL had a 16% greater hazard (HR=1.16, 95% CI=1.01-1.33). We did not find a statistically significant association between HDL-C and AD risk. CONCLUSION: People with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60s and 70s had modestly higher risk of AD than those with intermediate (160 mg/dL) levels. The extreme age bands (50s and 80s) had small sample sizes. J Am Geriatr Soc 66:2344-2352, 2018.
Key words: Alzheimer's disease; dementia; cholesterol C ardiovascular risk factors have been increasingly recognized as targets for reducing dementia in late-life, especially late-onset Alzheimer's disease (AD). 1, 2 One common modifiable cardiovascular risk factor is dyslipidemia, which affects more than half of US adults. 3 Some epidemiological studies have reported that midlife high total serum cholesterol (TC) is associated with greater risk of late-onset AD, 4 but the evidence is mixed. A 2017 meta-analysis using data from cohort studies on the association between serum cholesterol and risk of late-life cognitive decline detected significant gaps in the literature, including insufficient data to examine cholesterol subfractions (e.g., high-density lipoprotein cholesterol (HDL-C), non-HDL-C), sex differences, and apolipoprotein E (APOE) interactions. 4 Moreover, studies evaluating midlife cholesterol lacked clear information on age of cholesterol exposure. 4 To address some of these gaps, we evaluated extensive longitudinal clinical data from a prospective cohort with research-quality case ascertainment to determine associations between cholesterol levels at specific ages and subsequent AD risk. We hypothesized that serum cholesterol levels (HDL-C, non-HDL-C) would be associated with subsequent AD risk. Specifically, we hypothesized that higher non-HDL-C levels in individuals in the 50s to 70s would be associated with higher AD risk and that higher HDL-C levels would be associated with lower AD risk.
METHODS

Design, Study Setting, and Participants
The institutional review boards of Kaiser Permanente Washington (KPW) and the University of Washington reviewed and approved the research protocol for this population-based prospective cohort study. Participants provided written informed consent.
The Adult Changes in Thought (ACT) Study enrolled dementia-free consenting participants randomly sampled from Seattle-area KPW members aged 65 and older starting in 1994 to 1996. 5 Additional details of the ACT study have been previously reported. 5 ACT's Completeness of FollowUp Index (>97%) has been exemplary. 6 Our current analysis estimated associations between cholesterol exposures during specific age bands (50-59, 60-69, 70-79, 80-89) and subsequent risk of AD and other dementias. We identified separate, partially overlapping subcohorts of ACT participants for 4 exposure age band analyses ( Figure 1) . We describe the inclusion criteria for the age 60 to 69 subcohort in detail here; the other subcohorts followed analogous specifications. ACT participants included in the age 60 to 69 subcohort were required to have had at least 1 biennial follow-up visit on or after age 60, have at least 1 cholesterol measure (total cholesterol (TC) and HDL-C) recorded between the ages of 60 and 69, and be dementia free and under observation in ACT as of age 70 or older. Data through June 30, 2015, were included in these analyses. Of 4,368 participants with at least 1 biennial follow-up visit in the ACT Study, 1,088 were eligible for the age 50 to 59 analyses, 2,852 for the age 60 to 69 analyses, 2,344 for the age 70 to 79 analyses, and 537 for the age 80 to 89 analyses (Figure 2 ). Included and excluded participants are compared in Supplementary  Table S1 .
Identification of AD and Dementia
Participants were assessed using the Cognitive Abilities Screening Instrument (CASI) at study entry and subsequent biennial visits. CASI scores range from 0 to 100, with higher scores indicating better cognitive performance. 7 Participants with scores of 85 or less underwent a standardized diagnostic evaluation for dementia and a battery of neuropsychological tests. Results of these evaluations and laboratory and imaging records were then reviewed in a multidisciplinary consensus conference. 8 Diagnoses of dementia and probable or possible AD were made using research criteria. 9, 10 Dementia-free participants continued scheduled follow-up visits. Participants with new-onset dementia underwent at least 1 annual follow-up examination to confirm the diagnosis.
Cholesterol
Clinical measures of TC and HDL-C were captured for KPW members using computerized laboratory data from 1988 onward. Non-HDL-C levels were computed by subtracting HDL-C from TC. We computed the average observed cholesterol measures (HDL-C, non-HDL-C) for each ACT participant included in the 4 age-band analyses using all recorded measures in the laboratory database gathered during the specific age band.
APOE Genotype
APOE genotype data were available for 4,427 (87%) ACT participants. APOE genotype was determined using published methods and categorized as presence or absence of any ε4 alleles.
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Covariates
Based on a review of the literature, we selected covariates that may confound associations between cholesterol and AD risk. 4 Demographic factors included age, sex, selfreported race, and education (at least some college vs high school or less). Body mass index (BMI), measured at ACT visits and calculated as weight in kilograms divided by height in meters squared, was unavailable for many participants during the age band exposure window of interest because the window predated the individual's enrollment in ACT. As such, we imputed BMI during the age band of interest for each individual based on a mixed-effects model of BMI trajectories as a function of age and sex. The model used all participants' observed BMI measures across study visits and included main and interacting effects for age and sex, along with participant-specific random intercepts and slopes. Participants were asked about smoking status (ever vs never at ACT baseline). Participants were also asked about early-life socioeconomic status using a financial difficulty rating (range 1-10). Treatment for hypertension and diabetes mellitus was determined using KPW pharmacy data as receipt of at least 2 fills of a medication from the respective therapeutic class within a calendar year at any point during or before the cholesterol age band exposure window of interest.
Statins and Other Cholesterol-Lowering Drugs
Our primary goal was to investigate the effect of serum cholesterol levels as a biological risk factor for late-onset AD, independent of treatments used to achieve a certain cholesterol level. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) reduce TC and low-density lipoprotein cholesterol (and non-HDL-C), and some may increase HDL-C, and thus may affect cognitive decline and dementia. A recent systematic review highlighted that prior literature from randomized controlled trials and observational studies does not support a causal effect of statin use on cognitive decline or dementia, 12 so we decided a priori not to adjust for statin use in our primary analysis; we assessed the effect of this decision by performing sensitivity analyses adjusting for statin use and performing analyses separately for those who did not receive a statin during the 10-year age band when cholesterol was assessed.
Statistical Analysis
For each of the 4 age-band analyses, we estimated the association between average HDL-C and average non-HDL-C during the specified ages and risk of incident AD and allcause dementia. To estimate these associations, we used Cox regression with a separate model fit for each exposure (HDL-C, non-HDL-C) and outcome (AD, all-cause dementia) pair within a given age band sample. Age served as the time-axis for these models, with participants followed from subcohort entry to the earliest of outcome onset (event) or last study visit before September 30, 2015 (censoring) . Participants who withdrew from ACT or died before the end of the study period and before any outcome onset were censored at their last study visit. Timing of AD or dementia onset was set as the midpoint between the ACT visit that triggered the diagnosis and the preceding visit, as is ACT's convention. 13, 14 For the analyses of AD, onset of non-AD dementia was treated as a censoring event.
Average HDL-C and non-HDL-C exposures were included in Cox models using natural cubic splines with knots at the 10 th , 50 th , and 90 th percentiles of the cholesterol distribution for a given analysis to allow for the potential that associations between cholesterol and cognitive outcomes may be nonlinear, as has been suggested in other studies. (Further information regarding spline models is provided in Supplementary Appendix S1.) 15, 16 Adjustment covariates included sex, education, self-reported race, smoking history, treatment for hypertension or diabetes mellitus, BMI, and early-life socioeconomic status. In addition, we stratified Cox models according to ACT study cohort (original, expansion, continuous enrollment) and APOE genotype to account for the potentially different underlying baseline hazards due to calendar time and genetic risk. The estimated adjusted hazard ratios (HRs) with 95% confidence intervals were graphed, comparing hazards at various levels of HDL-C or non-HDL-C with hazards at a reference level. For clarity of presentation, for all figure panels we used a common reference level (55 mg/dL for HDL-C, 160 mg/dL for non-HDL-C) that was near the median for most age-band analyses. Overall tests of significance (twosided, alpha = .05) for the associations were performed based on a joint (omnibus) test of the null hypothesis that the model spline parameters were simultaneously 0. We assessed proportional hazards using Schoenfeld residuals.
For the age bands containing the largest sample sizes (60-69, 70-79), we performed additional subgroup analyses to investigate potential effect modification according to sex and APOE genotype. For these investigations, we fit separate models for men and women and separate models for those with and without an APOE ε4 allele. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and R, version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline Characteristics
Participants in younger age bands had more years of followup, higher proportions from the replacement ACT cohort (than from the original or expansion cohorts), and higher proportions with education beyond high school than those in older age bands (Table 1) . Average non-HDL-C levels were lower in the older age bands than in the younger age bands, whereas average HDL-C levels were similar across age bands.
AD, Dementia, and Cholesterol
Of the 3,565 participants included in complete case analyses, 877 developed all-cause dementia; 713 of these cases were possible or probable AD, 71 were vascular dementia, 38 were "other medical causes of dementia," 28 were of multiple etiologies, 4 were substance use-related dementia, and 23 were of other or unknown cause (data not shown). For the age bands containing the largest sample sizes (60-69, 70-79), 412 and 538 participants, respectively, developed possible or probable AD, and 514 and 647, respectively, developed all-cause dementia. Figures 3  and 4 (and Supplementary Tables S2 and S3) show the age band analyses of the adjusted association between HDL-C and non-HDL-C levels and AD. No statistically significant association was found in any of the age bands between HDL-C and AD (Figure 3 ). For the association between non-HDL-C and AD, a statistically significant association was found in the 60 to 69 (p = .005) and 70 to 79 age bands (p = .04), suggesting a potential U-shaped relationship with modestly higher risk at low and high levels ( Figure 4) . The association was strongest in the 60 to 69 age band, particularly at low levels of non-HDL-C. In that age band, for example, those with an average non-HDL-C of 120 mg/dL were 29% more likely to have AD than those with an average non-HDL-C of 160 mg/dL (HR=1.29, 95% CI=1.04-1.61), and those with an average of 210 mg/dL were 16% more likely (HR=1.16, 95% CI=1.01-1.33). The association for the 70 to 79 age band was less pronounced, with those with an average non-HDL-C of 120 mg/dL being 19% more likely than those with an average non-HDL-C of 160 mg/dL to have AD (HR=1.19, 95% CI=0.99-1.42) and those with an average of 210 mg/dL being 16% more likely (HR=1.16, 95% CI=1.00-1.34). For the outcome of all-cause dementia, we found similar results (Supplementary Figures S1 and S2 ).
Sensitivity Analyses: Sex, APOE Genotype, and Statin Use
For the age bands containing the largest sample sizes (60-69, 70-79), we performed stratified analyses according to sex and APOE genotype. For the outcome of AD, stratification according to sex did not reveal statistically significant associations with HDL-C exposure for women or men in either age band (Supplementary Figure S3) . For non-HDL-C, women with high average non-HDL-C levels (>220 mg/dL) during ages 60 to 69 had significantly greater AD risk than those with an average non-HDL-C level of 160 mg/dL (p = .01), a pattern seen similarly in men in that age band (although nonsignificant, p = .32). Conversely, during ages 70 to 79, a significant association was only seen in men and was in the opposite direction, with low average non-HDL-C levels associated with higher AD risk (p = .003) (Supplementary Figure S4) .
Stratifying according to APOE status for the association between HDL-C and AD found modest evidence of greater AD hazard with low HDL-C levels than with levels of 55 mg/dL during ages 60 to 69 in participants with 1 or more APOE ε4 allele (p = .04), an association not observed in those without an ε4 allele (p = .68) (Supplementary Figure S5) . This association was not seen in the age 70 to 79 analysis. Furthermore, stratification according to APOE genotype did not show significant associations with non-HDL-C exposure in any age subgroups (Supplementary JAGS DECEMBER 2018-VOL. 66, NO. 12 CHOLESTEROL AND ALZHEIMER'S DISEASE Figure S6 ). Similar results were found for all-cause dementia (Supplementary Figures S7-S10) . Adjusting for any statin use during the 10-year age band when cholesterol was assessed did not change the primary results (Supplementary Figures S11 and S12) , and performing analyses separately for those who did not receive a statin did not change the primary results ( Supplementary  Figures S13 and S14 ).
DISCUSSION
In our prospective community-based cohort study, we found an overall significant association between higher AD risk and non-HDL-C levels in the decades from 60 to 69 and 70 to 79. This finding revealed a potential U-shaped relationship with modestly higher AD risk at low and high levels of non-HDL-C. The association was strongest in the 60 to 69 age band, particularly at low levels of non-HDL-C. The association for the 70 to 79 age band was in the same direction but less pronounced. We did not find an association between HDL-C levels and subsequent AD risk.
Most studies that have investigated associations between cholesterol and AD risk have focused on total cholesterol as an exposure [17] [18] [19] [20] and have categorized (into quartiles [21] [22] [23] ) or dichotomized 17, 19 the measure, and they have yielded inconsistent results. 4, [17] [18] [19] [20] [21] [22] [23] [24] Evidence of a different risk of AD according to lipid fractions suggests the need to evaluate them separately. 4 Categorizing continuous variables comes at a cost, most notably concealing nonlinearity in associations between exposure and outcome. 25 Prior studies have also been limited by a small number of AD cases; the 8 studies we are aware of ranged from 27 19 to 532 24 cases, with a median of 91 and a total across all 8 studies of 1,153 AD cases. [17] [18] [19] [20] [21] [22] [23] [24] These studies did not investigate whether age at exposure to different levels of cholesterol mattered in terms of dementia risk.
To address some of these limitations, we evaluated data from a large cohort of well-characterized individuals with a large number of AD cases. We had approximately as many AD cases in each of our largest age bands (n=412, n=538) as in the largest single prior study we are aware of (n = 532). 24 Furthermore, our complete case analytical sample resulted in 713 unique possible or probable AD cases (877 all-cause dementia cases). The extensive clinical laboratory data available and the long-term follow-up of the cohort afforded us the opportunity to evaluate hazards associated with cholesterol levels using a spline model, so we could evaluate risk across the entire spectrum of observed cholesterol levels. This a priori modeling decision suggested a nonlinear, nonmonotonic association between non-HDL-C levels and AD risk. We found evidence of sex differences across age bands for the association between non-HDL-C and AD risk. Women with high non-HDL-C levels during ages 60 to 69 and men with low non-HDL-C levels during ages 70 to 79 were at greater risk of AD. Moreover, in those with 1 or more APOE ε4 alleles, low HDL-C levels were associated with greater AD risk. Although high levels of non-HDL-C are clearly associated with greater vascular risk, there is some evidence that low levels of non-HDL-C may also be associated with adverse outcomes, including intracerebral hemorrhage. 26 A previous study reported a significant association between low cholesterol levels and intracerebral hemorrhage in older men. 27 For the APOE finding, it is not clear whether low HDL-C levels reflect early AD development or accelerate AD pathogenesis.
Our main finding of a U-shaped association between AD and non-HDL-C levels during mid-to late life has biological plausibility. 22 Cholesterol is needed for normal neuronal functioning. Low cholesterol levels may indicate early manifestations of chronic disease, which may lead to cognitive impairment, frailty, and eventual AD. 22 Conversely, high cholesterol levels may accelerate AD pathogenesis. Evidence from a mouse model suggests that high dietary cholesterol increases Aβ accumulation and accelerates ADrelated pathology. 28 Future research is needed to explore potential mechanisms of age-varying risks of non-HDL-C and AD. Our primary findings do not take into account whether these low cholesterol levels are natural or therapeutically reduced. 29 Although we did not incorporate statins (or other lipid-lowering medications) into our primary analysis, sensitivity analyses adjusting for statin use and stratified analyses in those who did not receive a statin did not meaningfully change the overall results. Data on the association with long-term statin use will become available in the coming years.
Strengths of this study include the large sample with minimal attrition and prospective ascertainment of research-quality cases. Several limitations should be acknowledged. The potential for confounding by unmeasured or unknown factors cannot be excluded. We were limited to available cholesterol measures obtained at irregular intervals to estimate cholesterol exposures, as is the case Figure 3 . Age-varying association between high-density lipoprotein cholesterol (HDL-C) levels and Alzheimer's disease.
a Curves depict hazard ratios (with shading representing 95% confidence intervals) comparing average HDL-C level on the x-axis with a reference value of 55 mg/dL. Cholesterol level was modeled using natural cubic splines (with knots at 10%, 50%, and 90%-iles of exposure distributions); p-values provided are for joint (omnibus) tests of these spline parameters. Boxplots summarize distribution of average HDL-C levels observed in the sample. Models adjusted for sex, race, education, early life financial difficulty, smoking, treatment for hypertension or diabetes, and body mass index and stratified according to Adult Changes in Thought cohort and apolipoprotein E genotype.
with all clinical, real-world data. As such, we measured average cholesterol levels within decade-long age bands to summarize exposures at different ages. Others have assessed single cholesterol levels 4 or changes within individuals in cholesterol levels over time and their association with AD risk. 18 We did not have sufficient clinical data to estimate complex cholesterol exposure summaries. It is important to recognize that these different approaches to cholesterol exposure address different research questions, with our analysis revealing potentially important risk periods for subsequent AD. In addition, the youngest (50-59) and oldest (80-89) age bands had the smallest sample sizes, limiting our ability to estimate precise effects and draw conclusions. Our imputation of BMI values also deserves mention. To avoid inefficient analyses of complete cases requiring a BMI value, we chose to impute BMI using a mixed-effects model of BMI trajectories as a function of age and sex. The association between BMI and AD is mixed, 30 ,31 so we do not anticipate this analytical decision had a significant effect on our results. We did not have sufficient sample sizes of other types of dementias (e.g., vascular) to draw conclusions. Finally, our results may not be generalizable to other groups.
In conclusion, we found that people with low (120 mg/dL) and high (210 mg/dL) non-HDL-C levels during their 60's and 70s were at higher risk of AD and all-cause dementia than those with intermediate (160 mg/DL) levels.
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